StockData
Immunocore Holdings plc logo

Immunocore Holdings plc (IMCR) stock

IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3014% below fair value
$27.81−1.07 (-3.70%)

Close on Nov 17, 2026Market cap $1.43BP/E –Yield 0.00%

Immunocore total assets

Total assets on the balance sheet at the end of each period.

Immunocore's total assets was $1.12B at Jun 30, 2026. For fiscal 2025 it was $1.07B, up 5.7% from the year before.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.07B+5.7%
FY2024Dec 31, 2024$1.01B+69.1%
FY2023Dec 31, 2023$597.00M+13.3%
FY2022Dec 31, 2022$526.76M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.12B+3.4%
Q1 FY2026Mar 31, 2026$1.07B+4.3%
Q4 FY2025Dec 31, 2025$1.07B+5.7%
Q3 FY2025Sep 30, 2025$1.10B+1.6%
Q2 FY2025Jun 30, 2025$1.08B+5.8%
Q1 FY2025Mar 31, 2025$1.03B+3.4%
Q4 FY2024Dec 31, 2024$1.01B+69.1%
Q3 FY2024Sep 30, 2024$1.08B+105.9%
Q2 FY2024Jun 30, 2024$1.02B–
Q1 FY2024Mar 31, 2024$993.99M–
Q4 FY2023Dec 31, 2023$597.00M–
Q4 FY2022Dec 31, 2022$526.76M–

More Immunocore figures

See a number that looks wrong?